Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
In development [GID-TA10583] Expected publication date: TBC
Search results
563 results
-
-
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]
In development [GID-TA10571] Expected publication date: 25 August 2021
-
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]
In development [GID-TA10569] Expected publication date: TBC
-
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]
In development [GID-TA10568] Expected publication date: TBC
-
Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495
In development [GID-TA10395] Expected publication date: TBC
-
Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]
In development [GID-TA10616] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
In development [GID-TA10617] Expected publication date: TBC
-
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
In development [GID-TA10522] Expected publication date: TBC
-
Elotuzumab for multiple myeloma [ID966]
In development [GID-TA10134] Expected publication date: TBC
-
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
In development [GID-TA10380] Expected publication date: TBC
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-TA10642] Expected publication date: TBC
-
Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
In development [GID-TA10494] Expected publication date: TBC
-
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
In development [GID-TA10480] Expected publication date: TBC
-
Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264
In development [GID-TA10365] Expected publication date: TBC
-
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
In development [GID-TA10158] Expected publication date: TBC
-
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (ID1375)
In development [GID-TA10360] Expected publication date: TBC
-
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
In development [GID-TA10429] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
In development [GID-TA10295] Expected publication date: TBC
-
Short bowel syndrome - teduglutide [ID885]
In development [GID-TA10048] Expected publication date: TBC
-
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development [GID-TA10606] Expected publication date: 08 June 2022
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: 23 March 2022
-
Chronic kidney disease: assessment and management (update): draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 19 March 2021.
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
In development [GID-TA10701] Expected publication date: 20 July 2022
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 04 May 2022
-
Inducing labour (update)
In development [GID-NG10082] Expected publication date: 14 October 2021
-
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education
In development [GID-NG10113] Expected publication date: 19 January 2022
-
Rehabilitation after traumatic injury
In development [GID-NG10105] Expected publication date: 23 November 2021
-
Gout: diagnosis and management
In development [GID-NG10151] Expected publication date: 13 June 2022
-
Depression in adults: treatment and management (update)
In development [GID-CGWAVE0725] Expected publication date: 12 May 2022
-
Heart valve disease presenting in adults: investigation and management
In development [GID-NG10122] Expected publication date: 08 September 2021
-
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management
In development [GID-NG10185] Expected publication date: TBC
-
Neonatal infection: antibiotics for prevention and treatment
In development [GID-NG10111] Expected publication date: 12 April 2021
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: 21 April 2021
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 21 April 2021
-
Andexanet alfa for reversing anticoagulation [ID1101]
In development [GID-TA10440] Expected publication date: 14 April 2021
-
Chronic pain: assessment and management
In development [GID-NG10069] Expected publication date: 07 April 2021
-
Acne Vulgaris: Management
In development [GID-NG10109] Expected publication date: 09 June 2021
-
Mental health community settings
In development [GID-SGWAVE0702] Expected publication date: TBC
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
In development [GID-TA10667] Expected publication date: TBC
-
Vaccine uptake in the general population
In development [GID-NG10139] Expected publication date: 06 April 2022
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Pelvic floor dysfunction: prevention and non-surgical management
In development [GID-NG10123] Expected publication date: 09 December 2021
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: 05 May 2021
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 19 May 2021